ALX Oncology Holdings Inc.
NASDAQ:ALXO
0.9594 (USD) • At close March 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 1.182 | 4.796 | 2.067 |
| Cost of Revenue
| 0 | 0.836 | 1.466 | 0.736 | 1.075 | 4.36 | 1.88 |
| Gross Profit
| 0 | -0.836 | -1.466 | -0.736 | 0.107 | 0.436 | 0.187 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0.091 | 0.091 | 0.09 |
| Reseach & Development Expenses
| 116.373 | 141.795 | 98.4 | 60.17 | 28.961 | 16.306 | 11.27 |
| General & Administrative Expenses
| 26.094 | 28.483 | 29.036 | 23.385 | 14.809 | 3.313 | 2.601 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 26.094 | 28.483 | 29.036 | 23.385 | 14.809 | 3.313 | 2.601 |
| Other Expenses
| 0 | 0 | -0.26 | 0.084 | -0.404 | -0.005 | -0.002 |
| Operating Expenses
| 142.467 | 170.278 | 127.436 | 83.555 | 43.77 | 19.619 | 13.871 |
| Operating Income
| -142.467 | -170.278 | -127.436 | -83.555 | -43.663 | -19.183 | -13.684 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | -36.94 | -4 | -6.62 |
| Total Other Income Expenses Net
| 7.617 | 9.473 | 4.018 | 0.071 | -1.836 | -0.026 | -0.002 |
| Income Before Tax
| -134.85 | -160.805 | -123.418 | -83.484 | -45.499 | -19.209 | -13.686 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | -38.493 | -4.005 | -6.621 |
| Income Tax Expense
| 0 | 0 | 0.064 | -0.021 | 0.241 | 0.034 | 0.045 |
| Net Income
| -134.85 | -160.805 | -123.482 | -83.463 | -45.74 | -19.243 | -13.731 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | -38.697 | -4.012 | -6.643 |
| EPS
| -2.58 | -3.74 | -3.03 | -2.07 | -1.15 | -0.53 | -0.63 |
| EPS Diluted
| -2.58 | -3.74 | -3.03 | -2.07 | -1.15 | -0.53 | -0.63 |
| EBITDA
| -132.249 | -158.404 | -121.952 | -83.471 | -43.461 | -18.759 | -13.255 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | -37.282 | -3.911 | -6.413 |